Clinical Scorecard: Progress and Future Directions in Cellular Treatments for Leukemia and Myeloma

At a Glance

Key Highlights

• CAR-T therapies targeting BCMA (cilta-cel, ide-cel) have shown unprecedented responses in relapsed/refractory multiple myeloma but are not curative with relapse due to antigen escape and T-cell exhaustion.
• GPRC5D-directed CAR-T cells demonstrate higher overall and complete response rates with fewer relapses compared to BCMA CAR-T, offering a promising alternative especially after BCMA failure.
• HLA-mismatched peripheral blood stem cell microtransplant shows potential as a low-intensity, well-tolerated therapy with immune reconstitution benefits and notable survival outcomes in multiple myeloma.

Guideline-Based Recommendations

Diagnosis

• Identify relapsed/refractory multiple myeloma and high-risk smoldering myeloma through clinical and cytogenetic assessment.
• Use diagnostic criteria to differentiate smoldering myeloma from monoclonal gammopathy of undetermined significance and overt multiple myeloma.

Management

• Consider FDA-approved BCMA-targeted CAR-T therapies (cilta-cel, ide-cel) for relapsed/refractory multiple myeloma.
• Explore GPRC5D CAR-T therapy as an emerging option, particularly after BCMA CAR-T failure, pending further phase II/III validation.
• Evaluate HLA-mismatched peripheral blood stem cell microtransplant as a potential low-toxicity alternative therapy.
• Use daratumumab for high-risk smoldering myeloma to delay progression and improve survival.

Monitoring & Follow-up

• Monitor for relapse post-CAR-T therapy due to antigen escape and T-cell exhaustion.
• Assess for cytokine release syndrome and other toxicities, noting higher rates of high-grade CRS with BCMA CAR-T compared to GPRC5D CAR-T.
• Evaluate immune reconstitution markers following microtransplant therapy.

Risks

• Relapse after CAR-T therapy due to antigen escape and immunosuppressive marrow microenvironment.
• Potential cytokine release syndrome, with higher incidence in BCMA CAR-T therapies.
• Limited data on long-term outcomes and safety for emerging therapies such as GPRC5D CAR-T and microtransplant.

Patient & Prescribing Data

Patients with relapsed/refractory multiple myeloma and high-risk smoldering myeloma

FDA-approved BCMA CAR-T therapies show unprecedented responses but are limited by relapse; GPRC5D CAR-T offers promising efficacy and safety; daratumumab is approved for high-risk smoldering myeloma; microtransplant may provide a low-toxicity alternative with immune benefits.

Clinical Best Practices

• Select patients carefully for CAR-T therapies considering disease status and risk factors.
• Optimize post-CAR-T interventions to sustain efficacy and mitigate relapse.
• Consider emerging CAR-T targets like GPRC5D especially after BCMA therapy failure.
• Incorporate daratumumab for high-risk smoldering myeloma to delay progression.
• Explore low-intensity cellular therapies such as HLA-mismatched microtransplant in appropriate clinical trials.
• Ensure equitable access to cellular therapies through scalable production and distribution strategies.

References

• Yu et al. - Overview of CAR-T in Multiple Myeloma
• Yang et al. - Meta-analysis of BCMA and GPRC5D CAR-T in RRMM
• Lei et al. - HLA-mismatched Peripheral Blood Stem Cell Microtransplant in MM
• Garg and Devarakonda - Review of Daratumumab in Smoldering Myeloma